Sunday , December 17 2017
Home / Letter From The Editor / Editor’s Note, SGLT-2 Inhibitor Special Edition, April 2015

Editor’s Note, SGLT-2 Inhibitor Special Edition, April 2015

Beta cells are very important in the production of insulin as we all know, and when our patients are developing diabetes they actually turn up insulin production in the beta cells, so that when they are diagnosed many patients are actually making a lot of insulin. However this overproduction of insulin soon starts to wane and our patients become insulin deficient. Drugs like sulfonylureas and glitinides increase production, and the GLP-1 analogs and DPP-4 inhibitors can help with first phase insulin release, but as those cells continue to decline there has been no way to rejuvenate them. Now it appears that the use of SGLT-2 inhibitors can preserve and possibly regenerate beta cells with long term use.

This means that if we could combine an SGLT-2 with a DPP-4 inhibitor we might be able to increase insulin production without the use of a sulfonylurea while saving beta cell life.